Neulasta (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Neulasta, is a granulocyte colony-stimulating factor (G‑CSF) analog presented as a 6 mg/0.6 mL prefilled syringe solution for injection for subcutaneous use. It helps prevent chemotherapy‑induced neutropenia and supports stem cell mobilization in patients undergoing myelosuppressive therapy.

GNH USA supplies Neulasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Neulasta (pegfilgrastim) is a myeloid growth factor used to manage neutrophil deficiency associated with chemotherapy and stem cell collection.

- Chemotherapy‑induced neutropenia: reduces the incidence and duration of severe neutropenia in patients receiving myelosuppressive chemotherapy. - Stem cell mobilization for transplantation: enhances peripheral blood progenitor cell collection in donors prior to autologous or allogeneic stem cell transplantation.

Neulasta may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Bone pain: mild to moderate discomfort in bones or joints. - Injection site reactions: redness, swelling or itching at the injection site. - Headache: transient mild headache. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening. - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Leukocytosis: excessively high white blood cell count.

Neulasta requires careful clinical consideration before use.

- Assess baseline neutrophil count: verify patient’s absolute neutrophil count before administration. - Avoid concurrent myelosuppressive agents: do not give with other drugs that further suppress bone marrow. - Monitor for bone pain: provide analgesics as needed. - Use caution in patients with splenic disorders: increased risk of splenic complications. - Pregnancy and breastfeeding: safety not established; weigh benefits versus risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neulasta can interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Live vaccines: may increase infection risk; avoid within two weeks of administration. - Other G‑CSF products: additive effects on neutrophil counts; avoid simultaneous use.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce efficacy; monitor neutrophil response. - Chemotherapy agents: schedule timing to avoid overlapping peaks; monitor blood counts. - Anticoagulants: rare reports of bleeding; observe for signs of hemorrhage.